MAIA Biotechnology (MAIA) Change in Accured Expenses (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Change in Accured Expenses of -$458387.0 for Q1 2026, down 152.86% year-over-year from $867184.0 in Q1 2025, and up 84.83% quarter-over-quarter from -$3.0 million in Q4 2025.
MAIA Biotechnology (MAIA) Change in Accured Expenses (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Change in Accured Expenses for 6 consecutive years, with -$458387.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 152.86% year-over-year to -$458387.0; the TTM figure through Mar 2026 stood at $153384.0 (down 5.99% YoY), while the FY2025 annual figure was $1.5 million, up 250.95% from the prior year.
- Change in Accured Expenses rose to -$458387.0 in Q1 2026 per MAIA's latest filing, from -$3.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.5 million in Q3 2025 and bottomed at -$3.0 million in Q4 2025.
- Historically, Change in Accured Expenses has averaged $183908.2 across 5 years, with a median of $134763.0 in 2025.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses sank 3459.64% — and 2025, when it jumped 1574.67%.
- MAIA Biotechnology's Change in Accured Expenses stood at $663255.0 in 2022, then plunged by 43.7% to $373419.0 in 2023, then sank by 136.93% to -$137918.0 in 2024, then slumped by 2090.52% to -$3.0 million in 2025, then soared by 84.83% to -$458387.0 in 2026.
- Business Quant data shows MAIA's Change in Accured Expenses at -$458387.0 in Q1 2026, -$3.0 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | 80,749.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80,749.00 |
| Jun 30, 2026 | 80,749.00 |
| Mar 31, 2026 | -458,387.00 |
| Mar 31, 2026 | -458,387.00 |
| Dec 31, 2025 | -3.02 Mn |
| Dec 31, 2025 | -3.02 Mn |
| Sep 30, 2025 | 3.50 Mn |
| Sep 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 134,763.00 |
| Jun 30, 2025 | 134,763.00 |
| Mar 31, 2025 | 867,184.00 |
| Mar 31, 2025 | 867,184.00 |
| Dec 31, 2024 | -137,918.00 |
| Dec 31, 2024 | -137,918.00 |
| Sep 30, 2024 | 208,884.00 |
| Sep 30, 2024 | 208,884.00 |
| Jun 30, 2024 | -774,999.00 |
| Jun 30, 2024 | -774,999.00 |
| Mar 31, 2024 | -275,759.00 |
| Mar 31, 2024 | -275,759.00 |